Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer


如何引用文章

全文:

详细

Ovarian cancer (OC) is the fifth most common cancer in women in developed countries. Despite advances in treatment of epithelial OC: improving techniques and increasing aggressive surgery, the appearance of new cytostatics, targeted drugs, - the overall survival (OS) rates are unsatisfactory (the overall 5-year survival is 38%) and there is still an urgent need in development of new therapeutic agents to improve the results of treatment women with this disease. Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor, which demonstrates the high efficacy of treatment patients with OC associated with mutations in the BRCA genes. And olaparib is approved as a maintenance monotherapy in the treatment of women with platinum sensitive recurrent BRCA-associated OC. This review deals with the information concerning the efficiency and toxicity of olaparib, showing practical guidance on the application. The article focuses on the toxic effects of the drug, which can occur during olaparib therapy, and shows the guidance on management of the disease. Nausea, vomiting, fatigue and anemia are the most commonly reported side effects of olaparib application in clinical studies. Side effects are usually recorded in mild to moderate degree and nondurable. Using proper application and timely monitoring for side effects one can control many toxic actions.

作者简介

S Khokhlova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: svkhokhlova@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

参考

  1. Torre L.A, Brah F, Siegel R. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
  2. National Cancer Institute. SEER Stat Fact Sheets: Ovary Cancer. Available at: http://seer.cancer.gov/ statfacts/html/ovary.html Accessed April 21,2016.
  3. Press J.Z, DeLuca A, Boyd Netal Ovariancarcinomaswith genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8:17.
  4. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
  5. Daniels M.S, Babb S.A, King R.H et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol 2014; 32:1249- 556.
  6. Scott C.L, Swisher E.M, Kaufmann S.H. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015; 33:1397-406.
  7. Murai J, Huang S.Y, Das B.B. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72:5588-99.
  8. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
  9. Ledermann J, Harter P, Gourley C. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-92.
  10. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-61.
  11. Ledermann J.A, Harter P, Gourley C. et al. Overall sur-vival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. J Clin Oncol 2016; 34(Suppl 15): abst5501.
  12. Matulonis U, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy. Cancer 2016; 122:1844-52.
  13. Ledermann J, Harter P, Gourley C et al. Health-related quality of life (HRQoL) during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) and a BRCA mutation (BRCAm). European Society for Medical Oncology.
  14. Rolfo C, Swaisland H, Leunen K et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther 2015; 32:510-22.
  15. Astra Zeneca. LYNPARZA US label. 2016.
  16. Banerjee S, Ledermann J, Matulonis U et al. Managementof nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib. European Cancer Congress; 25-29 September 2015, Vienna, Austria; abst 2759.
  17. Matulonis U, Friedlander M, du Bois A et al. Frequency, severity and timing of common ad-verse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).J Clin Oncol 2015; 33 (Suppl. 15): abst5550.
  18. Sanchez R.I, Wang R.W, Newton D.J. et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32:1287-92.
  19. Hong J.H, Omur-Ozbek P, Stanek B.T. et al. Taste and odor abnormalities in cancer patients.J Support Oncol 2009; 7:58-65.
  20. Hovan A.J, Williams P.I.M, Stevenson-Moore P. et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 2010; 18: 1081-7.
  21. Berteretche M.V, Dalix A.M, d’Ornano A.M. et al. Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 2004; 12:571-6.
  22. Rehwaldt M, Wickham R, Purl S et al. Self-care strategies to cope with taste changes after chemotherapy Oncol Nurs Forum 2009; 36: E47-56.
  23. Patel A.G, Sarkaria J.N, Kaufmann S.H. Nonhomologous end joining drivespoly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA 2011; 108: 3406-11.

版权所有 © Consilium Medicum, 2017

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##